找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Analysis File of Drug-Induced Lung Injury; Expert Opinion for A Akihiko Gemma Book 2024 The Editor(s) (if applicable) and The Author(s), un

[复制链接]
楼主: Fuctionary
发表于 2025-3-23 11:26:39 | 显示全部楼层
发表于 2025-3-23 15:36:41 | 显示全部楼层
Špela Orehek,Gregor Petrič,Jan ŠinigojAlthough the mechanism of onset of lung injuries induced by drugs has not been clearly identified, it has been generally accepted that the pathologic condition occurs through direct cellular damages or indirect ones by inflammatory reactions, an immunological mechanism, by drugs or their intermediate metabolites [1].
发表于 2025-3-23 19:28:45 | 显示全部楼层
发表于 2025-3-23 22:56:16 | 显示全部楼层
发表于 2025-3-24 02:35:55 | 显示全部楼层
发表于 2025-3-24 10:07:56 | 显示全部楼层
HCI International 2020 - PostersAs a result of clinical studies, interstitial pneumonia is listed among important toxic events associated with the use of neoangiogenesis inhibitors. This information is included in the package insert. In this section, sunitinib, sorafenib, and bevacizumab, which were investigated in the post-marketing all-case survey are explained.
发表于 2025-3-24 12:05:34 | 显示全部楼层
Exposure Compensation from a Single ImageThe drug was used as an ALK inhibitor clinically at its first approval, and since then the indications have been expanded.
发表于 2025-3-24 15:50:00 | 显示全部楼层
发表于 2025-3-24 19:39:09 | 显示全部楼层
Anti-EGFR Antibodies (Cetuximab, Panitumumab, and Necitumumab)Study period: September 2008–January 2009 [2, 3].
发表于 2025-3-25 02:57:12 | 显示全部楼层
Proteasome Inhibitor (Bortezomib)Bortezomib (Velcade) was approved for the production and sale on October 20, 2006, and was launched on December 1, 2006. At that time, this drug was placed as a specific medicine for multiple myeloma.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-1 17:41
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表